CDK8/19-IN-1 NEW
| Price | $1820 | $2380 | $3100 |
| Package | 25mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-22 |
Product Details
| Product Name: CDK8/19-IN-1 | CAS No.: 1818427-07-4 |
| Supply Ability: 10g | Release date: 2026/05/22 |
Product Introduction
Bioactivity
| Name | CDK8/19-IN-1 |
| Description | CDK8/19-IN-1 is a selective, orally bioavailable dual inhibitor of CDK8 and CDK19, with IC50 values of 0.46 nM for CDK8, 0.99 nM for CDK19, and 270 nM for [CDK9]. |
| In vitro | CDK8/19-IN-1 (52h) weakly inhibits CDK2, achieving 62% inhibition at 1 μM. At 1 μM, it exhibits >50% inhibition against GSK3β, PLK1, ASK1, CK1δ, PKA, ROCK1, PKCθ, and CDC7. The compound shows dissociation constants (Kds) of 25, 46, 81, 86, 97, 160, and >3000 nM for CDK19, CDK8, DYRK1B, HASPIN, YSK4, HIPK1, and EPHA3, respectively. CDK8/19-IN-1 demonstrates potent antitumor activity with GI50 values ranging from 0.43 to 2.5 nM for colon, multiple myeloma, acute myelogenous leukemia (AML), and lung cancer cells. |
| In vivo | In mice bearing RPMI8226 human hematopoietic and lymphoid cells, CDK8/19-IN-1 (1.25 mg/kg twice daily or 2.5 mg/kg once daily, p.o.) significantly suppresses tumor growth. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | CDK9 | CDK8/CycC | CDK8/19-IN-1 | CDK-8/19-IN-1 | CDK8/19IN1 | CDK8/19 IN 1 | CDK19/CycC |
| Inhibitors Related | Ribociclib | Aceglutamide | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | 2,4,6-Trihydroxybenzoic acid | Dinaciclib |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1110.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
| $32.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-21 | |
|
VIP2Y
|
Shenzhen Nexcon Pharmatechs Ltd.
|
2026-07-07 | ||
| $3100.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY